Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double-blinded placebo-controlled interventional study

By Gao Y, Li Y, Tan Y, et al
Published June 15, 2021

Key Takeaways

Researchers conducted the study for analyzing the efficacy of novel cannabidiol (CBD) and aspartame formulation, JW-100, in relieving signs and symptoms of atopic dermatitis (AD). They performed a double-blinded placebo-controlled interventional study in which patients were randomly assigned to one of three treatment groups: JW-100 (CBD plus aspartame), CBD only, or placebo topical formulations. The trial was completed by 57 patients, who were included in the final analysis. Data reported that the Investigator’s Static Global Assessment score of the patients at baseline was 2.56, 2.24, and 2.24, for the JW-100, CBD, and placebo groups, respectively. Following 14 days of topical application, JW-100, a novel topical formulation containing CBD and aspartame, was shown to produce statistically significant improvements in AD.

Read the full article on Journal of Cosmetic Dermatology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter